Jubilant Pharmova Limited (JUBLPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹154B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated yesterday
Share price −1.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹805.31 – ₹1,238 · fair‑value band ₹361.01 – ₹638.73 · the ₹973.20 price screens above the ₹491.33 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jubilant Pharmova Limited (JUBLPHARMA) currently trades at ₹973.20, while our model-based Fair Value estimate is ₹491.33 — implying the stock looks roughly 49.5% overvalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Jubilant Pharmova Limited generated revenue of ₹82.8B at a net margin of 4.8%. Revenue grew 18.7% year over year. It earns a return on equity of 6.0%. Net debt stands at ₹23.5B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Jubilant Pharmova Limited reported revenue of ₹82.8B in FY2026 versus ₹61.3B in FY2022, a compound +7.8%/yr. Reported net income was ₹4.0B in FY2026, compounding −0.9%/yr from FY2022.
Is JUBLPHARMA fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jubilant Pharmova Limited (JUBLPHARMA) undervalued?
What is the fair value of JUBLPHARMA?
What is the quality score of JUBLPHARMA?
What is the revenue of Jubilant Pharmova Limited (JUBLPHARMA)?
What is the net profit margin of JUBLPHARMA?
Does Jubilant Pharmova Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.